Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-228 in previously treated metastatic renal cell carcinoma
NCT03097328Phase 2Completed
- Start
- Aug 2017
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
A Phase 2 trial of sapanisertib in metastatic renal cell carcinoma (mRCC). Started Aug 2017; status: completed.
02
Drugs
sapanisertib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT03097328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097328.